Juno Therapeutics to take on the University of Pennsylvania in legal showdown over next-generation cancer therapy.

Juno Therapeutics, an oncology startup founded last month with $120m venture backing, is starting 2014 with a legal battle against the University of Pennsylvania over the rights to next generation cancer therapies.

The dispute is over chimeric antigen receptors (CARs) which, as reported last month, are capable of reprogramming T-Cells, one of the body’s natural defence mechanisms, to identify and target cancer cells.

The opening round came when St Jude Children’s Research Centre – one of the three founding…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?